Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

NCT01624727 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

Interventions

  • DIETARY_SUPPLEMENT Omega 3 acid ethyl esters

Study Locations (2)

Massachusetts

  • Beth Israel Deaconess Medical Center — Boston
  • South Shore Medical Group — Milton

Trial Details

FieldValue
Enrollment Target 338 participants
Start Date 2009-06
Est. Completion 2015-01-15
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01624727

The ClinicalTrials.gov registry entry for NCT01624727 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 1 intervention — of which Omega 3 acid ethyl esters is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01624727 reports 2 study locations spanning 1 distinct geographic area — top geographies include Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01624727 about?

NCT01624727 is a clinical study titled "Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids". The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

What is the current status of trial NCT01624727?

This trial is currently completed. It is a NA study. The enrollment target is 338 participants. The study started on 2009-06. Estimated completion is 2015-01-15.

What conditions does trial NCT01624727 study?

This clinical trial studies the following conditions: Metabolic Syndrome, Coronary Heart Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01624727?

The interventions under investigation include: Omega 3 acid ethyl esters (DIETARY_SUPPLEMENT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01624727?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01624727 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial